Zydus, Cadila to buy part of Heinz India biz for Rs 4,595 cr
Consumer brands Complan, Glucon-D, Nycil, Sampriti Ghee to change hands24-10-2018
24-10-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Company has planned investor interaction through a conference call on November 3, 2018 at 5:30 p.m., post announcement of unaudited financial results for the quarter / half year ended on September 30, 2018.24-10-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed a Press Release with regard to proposed acquisition of 100% equity share capital of Heinz India Private Limited jointly with Zydus Wellness Limited.24-10-2018
Announcement under Regulation 30 (LODR)-Acquisition
We would like to inform that the Company has signed share purchase agreement jointly with Zydus Wellness Limited for proposed acquisition of 100% equity share capital of Heinz India Private Limited.24-10-2018
Zydus Cadila gets USFDA nod to market generic seizures treatment drug
Drug firm Zydus Cadila on Tuesday said it has received final nod from the US health regulator to market generic Clobazam tablets used for treatment o23-10-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We enclose herewith a copy of press release dated October 23, 2018 titled 'Zydus receives final approval from the USFDA for Clobazam Tablets'.23-10-2018
Board Meeting Intimation for Approval Of Half Yearly Unaudited Financial Results For The Quarter / Half Year Ended On September 30, 2018.
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2018 ,inter alia, to consider and approve The meeting of the Board of Directors of the Company will be held on Saturday, November 3, 2018 to consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2018. Further, as per code of conduct for prevention of Insider...19-10-2018
Zydus Cadila gets USFDA nod for generic gout attacks drug
Drug firm Zydus Cadila Thursday said it has received a tentative nod to market generic Colchicine tablets used for prevention and treatment of gout a18-10-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Colchicine Tablets18-10-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Clobetasol Propionate Cream17-10-2018